Education
About Us
Working with TipRanks
Follow Us
Moderna (DE:0QF)
:0QF
Earnings Data
Report Date
Feb 19, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-2.35Last Year’s EPS
-2.52Same Quarter Last Year
Based on 20 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements in cost reduction, strategic partnerships, and product approvals. However, these positives were tempered by notable challenges, including a significant revenue decline, a net loss for the quarter, and the discontinuation of the CMV vaccine program.Company Guidance
Cost Reduction Achievements
Moderna achieved a 34% reduction in cost of sales, R&D, and SG&A combined compared to Q3 2024 and a $2.1 billion improvement in costs over the last four quarters.
Strategic Partnerships Progress
Moderna established manufacturing facilities and multiyear offtake agreements with Canada, the U.K., and Australia, delivering the first made-in-Canada mRNA vaccines and obtaining regulatory licenses for facilities in the U.K. and Australia.
mNEXSPIKE and Spikevax Approvals
mNEXSPIKE was approved in the U.S. and Canada for the 2025-2026 season, and Spikevax received approval in 40 countries for the same period.
Cash and Investment Position
Moderna ended Q3 with $6.6 billion in cash and investments, with a projected year-end balance of $6.5 billion to $7 billion, indicating effective financial management.
Oncology and Rare Diseases Pipeline
Encouraging progress in oncology, including Phase Ib data for mRNA-4359, and target enrollment reached for the propionic acidemia registrational study.
DE:0QF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:0QF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 06, 2025 | €20.59 | €20.57 | -0.10% |
Aug 01, 2025 | €26.77 | €23.61 | -11.80% |
Feb 14, 2025 | €29.52 | €31.65 | +7.20% |
Nov 07, 2024 | €48.12 | €48.09 | -0.04% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Moderna (DE:0QF) report earnings?
Moderna (DE:0QF) is schdueled to report earning on Feb 19, 2026, Before Open (Confirmed).
What is Moderna (DE:0QF) earnings time?
Moderna (DE:0QF) earnings time is at Feb 19, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Moderna stock?
The P/E ratio of Moderna is N/A.
What is DE:0QF EPS forecast?
DE:0QF EPS forecast for the fiscal quarter 2025 (Q4) is -2.35.
